Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
Top
..
c19early.org COVID-19 treatment researchSelect treatment..Select..
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Escitalopram for COVID-19

Escitalopram has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Adamu et al., Evaluating The Antiviral Potential Of Fluoxetine, Sertraline, And Escitalopram Against SARS-CoV-2 In Vero Cells: A Drug Repurposing Study, IOSR Journal of Dental and Medical Sciences, doi:10.9790/0853-2310065564
Background: COVID-19, caused by SARS-CoV-2, remains a global health crisis with limited therapeutic options. Despite the availability of vaccines, the rapid evolution of viral variants necessitates the exploration of alternative treatments. Drug repositioning, the use of existing medications for new therapeutic indications, offers a promising approach. Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, and escitalopram have shown potential antiviral properties due to their immunomodulatory effects. This study investigates the impact of these SSRIs on SARS-CoV-2-induced cytopathic effects (CPE) in Vero cells. Materials and Methods: Vero cells were cultured and treated with varying concentrations of fluoxetine, sertraline, and escitalopram. Ivermectin, was used as a positive control. The cytotoxicity of these drugs was assessed using the Neutral Red assay. After viral infection of the cells, cytopathic effects were measured to determine the antiviral activity of the drugs. IC50 (half-maximal inhibitory concentration) values were calculated for each drug, and the results were compared using statistical analysis. Results: Fluoxetine, sertraline, and escitalopram demonstrated dose-dependent inhibition of SARS-CoV-2- induced cytopathic effects, with escitalopram showing the highest efficacy (IC50 = 0.02557 µM, p < 0.03). The selectivity indices (SI) for fluoxetine, sertraline, and escitalopram were significantly higher than that of ivermectin, indicating their safety at higher doses. Escitalopram exhibited superior antiviral activity, with up to 38% inhibition of SARS-CoV-2-induced CPE, compared to ivermectin's 10%. Conclusion: Fluoxetine, sertraline, and escitalopram, particularly escitalopram, are promising candidates for treating SARS-CoV-2 infections. These SSRIs exhibit significant inhibition of virus-induced cytopathic effects in Vero cells, suggesting their potential use as therapeutic agents against COVID-19. Further studies are requiredto confirm their clinical efficacy and safety in human subjects.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit